Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer

NCT ID NCT07660211

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called 177Lu-PSMA-VG01 in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has spread and stopped responding to hormone therapy. The drug is designed to deliver radiation directly to cancer cells, aiming to shrink tumors while limiting damage to healthy tissue. The study focuses on safety, how the drug moves through the body, and whether it shows any signs of fighting the cancer.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
177Lu-PSMA-VG01 (a radioactive molecule that targets prostate cancer cells)
What this could lead to
If successful, this could lead to a new treatment option for men with advanced prostate cancer that has spread and no longer responds to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 10 participants, so safety and effectiveness are not yet established. The radioactive drug may cause side effects like damage to healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhong Shan Hospital Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.